These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8115782)

  • 1. On the estimation of survival.
    Henson DE; Ries LA
    Semin Surg Oncol; 1994; 10(1):2-6. PubMed ID: 8115782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality rates by stage-at-diagnosis.
    Clinton K
    Semin Surg Oncol; 1994; 10(1):7-11. PubMed ID: 8115787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the utility of cancer-registry-processed cause of death in calculating cancer-specific survival.
    Hu CY; Xing Y; Cormier JN; Chang GJ
    Cancer; 2013 May; 119(10):1900-7. PubMed ID: 23408226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival studies: Cracow Cancer Registry experience.
    Pawlega J
    Cancer Detect Prev; 1993; 17(4-5):475-83. PubMed ID: 8242647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stage at diagnosis and early mortality from cancer in England.
    McPhail S; Johnson S; Greenberg D; Peake M; Rous B
    Br J Cancer; 2015 Mar; 112 Suppl 1(Suppl 1):S108-15. PubMed ID: 25734389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing non-cancer-related health status of US cancer patients: other-cause survival and comorbidity prevalence.
    Cho H; Mariotto AB; Mann BS; Klabunde CN; Feuer EJ
    Am J Epidemiol; 2013 Aug; 178(3):339-49. PubMed ID: 23825168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer survival in Germany and the United States at the beginning of the 21st century: an up-to-date comparison by period analysis.
    Gondos A; Arndt V; Holleczek B; Stegmaier C; Ziegler H; Brenner H
    Int J Cancer; 2007 Jul; 121(2):395-400. PubMed ID: 17372898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expected years of life lost for six potentially preventable cancers in the United States.
    Liu PH; Wang JD; Keating NL
    Prev Med; 2013 May; 56(5):309-13. PubMed ID: 23428566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How should we value lives lost to cancer?
    Ramsey SD
    J Natl Cancer Inst; 2008 Dec; 100(24):1742-3. PubMed ID: 19066279
    [No Abstract]   [Full Text] [Related]  

  • 10. Conditional survival of cancer patients: an Australian perspective.
    Yu XQ; Baade PD; O'Connell DL
    BMC Cancer; 2012 Oct; 12():460. PubMed ID: 23043308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of state-specific life tables on relative survival.
    Stroup AM; Cho H; Scoppa SM; Weir HK; Mariotto AB
    J Natl Cancer Inst Monogr; 2014 Nov; 2014(49):218-27. PubMed ID: 25417235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timely disclosure of progress in long-term cancer survival: the boomerang method substantially improved estimates in a comparative study.
    Brenner H; Jansen L
    J Clin Epidemiol; 2016 Feb; 70():224-32. PubMed ID: 26456902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probabilities of dying from cancer and other causes in French cancer patients based on an unbiased estimator of net survival: a study of five common cancers.
    Charvat H; Bossard N; Daubisse L; Binder F; Belot A; Remontet L
    Cancer Epidemiol; 2013 Dec; 37(6):857-63. PubMed ID: 24063904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditional relative survival of cancer patients and conditional probability of death: a French National Database analysis.
    Bouvier AM; Remontet L; Hédelin G; Launoy G; Jooste V; Grosclaude P; Belot A; Lacour B; Estève J; Bossard N; Faivre J;
    Cancer; 2009 Oct; 115(19):4616-24. PubMed ID: 19569252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts.
    Hassett MJ; Ritzwoller DP; Taback N; Carroll N; Cronin AM; Ting GV; Schrag D; Warren JL; Hornbrook MC; Weeks JC
    Med Care; 2014 Oct; 52(10):e65-73. PubMed ID: 23222531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conditional median survival of patients with advanced carcinoma: surveillance, epidemiology, and end results data.
    Kato I; Severson RK; Schwartz AG
    Cancer; 2001 Oct; 92(8):2211-9. PubMed ID: 11596040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjusting relative survival estimates for cancer mortality in the general population.
    Ellison LF
    Health Rep; 2014 Nov; 25(11):3-9. PubMed ID: 25408490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial/ethnic disparities in de novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer.
    Akinyemiju T; Sakhuja S; Waterbor J; Pisu M; Altekruse SF
    Cancer Med; 2018 Apr; 7(4):1183-1193. PubMed ID: 29479835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leading cancers--changes in five-year relative survival.
    Ellison LF; Gibbons L
    Health Rep; 2004 Mar; 15(2):19-32. PubMed ID: 15151028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer survival improving. Treatments, early diagnosis key.
    Mayo Clin Health Lett; 2006 Nov; 24(11):1-3. PubMed ID: 17219631
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.